Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Jul 10.
Published in final edited form as: Am J Med Genet A. 2009 Feb 15;0(4):573–583. doi: 10.1002/ajmg.a.32729

The Phenotype of Persons Having Mosaicism for Trisomy 21/Down Syndrome Reflects the Percentage of Trisomic Cells Present in Different Tissues

Paulie Papavassiliou 1, Timothy P York 1,4, Nurcan Gursoy 1,2, Gloria Hill 1,3, Lauren Vanner Nicely 1, Usha Sundaram 1, Allison McClain 1, Steven H Aggen 4, Lindon Eaves 1,4, Brien Riley 1,4, Colleen Jackson-Cook 1,5,*
PMCID: PMC3707311  NIHMSID: NIHMS484036  PMID: 19291777

Abstract

Little is known about the pathogenesis of the phenotype in individuals with trisomy 21 mosaicism and Down syndrome. The primary goal of this study was to identify factors contributing to the observed phenotypic variation by evaluating 107 individuals having trisomy 21 mosaicism. To investigate a potential “threshold” effect due to trisomic imbalance, lymphocyte and buccal mucosa nuclei were scored using FISH. Overall, buccal cells showed a significantly higher frequency of trisomy than lymphocytes (P< 0.0001). Using latent class analysis, two phenotypic classes were identified based on the clinical findings of the propositi. Patients from class 1 had significantly fewer traits and a lower percentage of trisomic cells (mean of 37.3% lymphocytes; 34.5% buccal mucosa cells) when compared to those stratified into class 2 (54.0% lymphocytes; 53.4% buccal mucosa cells). Tissue-specific influences were also detected, with buccal mucosa trisomy levels being significantly correlated with IQ (P = 0.0094; both ectodermal derivatives), while congenital heart defects were significantly correlated with lymphocytes (P = 0.0286; both mesodermal embryonic derivatives). In conclusion, allowing for the distinction of two groups, we observed variation in phenotype, associated with the percentage of trisomic cells. We also observed tissue-specific effects on phenotype. The results of this study should enable geneticists and other health care professionals to provide information regarding optimal diagnostic approaches and anticipated clinical outcomes.

Keywords: trisomy 21 mosaicism, mosaicism, Down syndrome, karyotype/phenotype correlation, fluorescence in situ hybridization, aneuploidy

INTRODUCTION

Down syndrome is the most common chromosomal abnormality in live-born individuals, occurring at a frequency of about 1/800 live births [reviewed by Patterson and Costa, 2005]. Most (90–95%) individuals with Down syndrome have trisomy for chromosome 21 [Pangalos et al., 1994]. Two to four percent of individuals with Down syndrome have a trisomic dose of the long arm of chromosome 21 as a result of a structural chromosomal abnormality (translocation or isochromosome) [Pangalos et al., 1994]. Mosaicism is seen in another two to four percent of individuals diagnosed with Down syndrome [Hamerton et al., 1965; Richards, 1969; Mikkelsen, 1977; Hook, 1981]. Mosaicism is a condition in which an individual has two or more genetically distinct cell lines that develop from a single zygote [Nussbam et al., 2001]. In the case of trisomy 21 mosaicism and Down syndrome, affected individuals have both trisomic (47,XX,+21 or 47,XY,+21) and euploid (46,XX or 46,XY) cell lines. The primary goal of this study was to determine if there are correlations between the phenotypic traits and the proportion of trisomic cells present in individuals having mosaicism.

An investigation involving individuals with trisomy 21 mosaicism can further our understanding of the mechanisms underlying the phenotype of Down syndrome since individuals with trisomy 21 mosaicism show a broad spectrum of clinical findings, ranging from traits typically seen in “complete” trisomy 21 (people having trisomy 21 in every cell) to that of a near normal phenotype [Finley et al., 1966; Shipe et al., 1968; Johnson and Abelson, 1969; Fishler and Koch, 1991; Bhatt et al., 1995]. Our knowledge of factors influencing the clinical outcome in individuals with MDS has been limited due to the relatively small number of cases of this rare condition that are available for study, with most investigators presenting either single case reports or findings from a small number of patients [reviewed by Papavassiliou, 2007]. These previously reported investigations were also accomplished prior to the advent offluorescent in situ hybridization (FISH)techniques, and were thus limited to the study of metaphase chromosomes following in vitro culturing, the latter of which could potentially skew the levels of trisomy detected.

Possible factors contributing to the broad spectrum of traits observed in persons with trisomy 21 mosaicism include (but are not limited to) variation in the proportion of trisomic cells present: (1) between individuals; and (2) from tissue to tissue within and/or between individuals. In this study of persons having trisomy 21 mosaicism, we quantified and compared the percentage of trisomic cells present in nuclei from both lymphocytes (cultured and uncultured) and buccal mucosa cells (uncultured). Thus, the level of trisomy was not only assessed in different tissues, but also from cells with and without the effect of in vitro culturing. The phenotypic profiles of the study subjects were also analyzed, using a latent class analysis (LCA), to determine if subgroups could be identified based on the patients’ phenotype, and if these distinct groups could be distinguished from one another based on their ratio of euploid to trisomic cells. The specific aims of this study were to test the following hypotheses: (1) The proportion of trisomic cells present in different tissues (blood and buccal mucosa) influences the phenotypic outcome associated with mosaicism for trisomy 21 in Down syndrome; and (2) Trisomic levels in buccal mucosa cells are more closely correlated with phenotypic findings of ectodermal origin, while trisomic levels in lymphocytes are more strongly correlated with findings of mesodermal origin.

MATERIALS AND METHODS

Human Subject Involvement

A total of 107 individuals with mosaicism for trisomy 21(propositi) was ascertained through parental support groups [National Down Syndrome Congress (NDSC), International Mosaic/Down Syndrome Association meetings, newsletters, and websites]. The only selection criterion was that the child had a chromosomally confirmed diagnosis of mosaicism for trisomy 21. After giving their informed consent (assent for children) (Virginia Commonwealth University IRB Committee, protocol # 0179) the study participants had the option to provide: (1) blood samples; (2) buccal smears (one from each cheek); (3) a completed questionnaire (which included queries regarding physical characteristics, health history, developmental progress, pregnancy history, and lifestyle); (4) pictures; (5) medical records; and/or (6) IQ reports/developmental information. Participating families could elect to provide all or only a portion of the items noted above. Questionnaire and medical record information was also collected from individuals with complete trisomy 21 (positive control group), who were also ascertained through parental support groups.

Evaluation of the Proportion of Cells With Trisomy 21

Lymphocyte preparations

Duplicate lymphocyte cultures were established and harvested according to standard protocols [Moorhead et al, 1960]. In order to quantify the proportion of trisomic cells in uncultured specimens, peripheral blood smear slides were made from each sample according to standard protocols.

Buccal mucosa cellular preparations

Buccal mucosa slides were made by the study subjects (or with parental assistance for younger subjects). The cells were collected by the subjects rubbing the inside of their cheek with a toothbrush and then spreading the collected cells directly onto positively charged slides (Fisher Scientific, Pittsburgh, PA). This procedure was repeated for the other cheek, with both slides being air-dried prior to shipment of the specimens. Upon receipt in the lab, these buccal smear slides were stored at −20°C until FISH was performed (approximately 1 week to 2 months later).

FISH methodology

The number of chromosomes 21 in interphase nuclei from cultured and uncultured lymphocytes and uncultured buccal mucosa cells was determined using FISH. The test probe used was one that is localized to 21q22.13–21q22.2 (D21S259\D21S341\D21S342) (Abbott Laboratories, Des Plaines, Illinois). In addition, a control probe for chromosome 13 (RB1 locus at 13q14; Abbott Laboratories) was also evaluated. The FISH on cultured lymphocytes was performed according to the probe manufacturer’s protocol (Abbott Laboratories). FISH on the uncultured specimens (buccal mucosa cells and uncultured lymphocytes) was done as described previously by Leach et al. [2004], with the adaptation that the uncultured lymphocytes were digested in a protease pretreatment solution (NaSCN; Abbott Laboratories) for 10 min rather than 30 min, as is done for the buccal cells.

Scoring frequency of trisomic cells

Probe signals were visualized using a Zeiss epifluorescent Axiskop equipped with single (SpectrumOrange™, SpectrumGreen™) and triple band pass filters. When scoring each cell, all focal planes were viewed to ensure the detection of all signals in the three-dimensional nuclei. Interphase nuclei that did not have clear borders or that were overlapping were excluded from the analysis. A total of 1000 cultured blood lymphocyte nuclei, 500 uncultured blood nuclei, and 500 buccal cells (250 per cheek) were scored for each study participant. Thus, using the probability cutoff value of 0.05, the evaluation of 1000 or 500 cells with our probes (which demonstrated 0.99% analytic sensitivity level) allowed for the detection of as low as 1.6% or 1.8% trisomic cells, respectively [Dewald et al., 1998]. In addition to interphase nuclei, 30 to 50 metaphase spreads were also analyzed from cultured lymphocyte samples.

Phenotype Assessment

The phenotypic findings present in each propositus having mosaicism were identified by certified (American Board of Medical Genetics) medical geneticists. Evaluations were done using one or more of the following assessment tools: (1) direct physical examination; (2) evaluations of photographs; and/or (3) a review of survey responses and medical records, the latter of which were obtained, with permission, as described above. Clinically relevant findings were summarized based on the criteria established by Epstein et al. [1991].

Statistical Analyses and Data Interpretation

A paired t-test was used to compare the frequencies of trisomic cells present amongst the collected samples (e.g., cultured blood vs. uncultured blood; cultured blood vs. buccal mucosa cells). Trait comparisons were done using a Pearson correlation analysis or a contingency Chi-square test. All statistical comparisons were performed using a significance level of α = 0.05.

Latent class analysis (LCA) was used to model subtypes of mosaicism by representing them as latent (“unmeasured”) variables [Muthén and Muthén, 1998]. Models were tested with 1, 2, and 3 classes. The model parameters were: (1) the prevalence of each latent class; and (2) the conditional response probabilities (the probability that a randomly selected member of particular latent class would have a positive response to a query regarding a particular phenotypic item). A subset of 25 phenotypic variables (Tables II and III) that were reported (present or absent) in 65% or more of the cases was used in the LCA analysis.

TABLE II.

Summary of Physical Stigmata Reported in 104 Mosaic Probands

Clinical finding Proportiona
having trait
% reporting
data
(response
rate)
Cyanotic CHDb 1/99 = 0.010 95%
Celiac disease 1/100= 0.010 96%
Hirschsprung’s disease 1/100= 0.010 96%
Imperforate anus 1/100= 0.010 96%
Esophageal stricture 2/100= 0.020 96%
Congenital/acquired cataracts 2/93 =0.022 89%
Leukemia 3/98 =0.031 94%
Duodenal stenosis/atresia 4/100= 0.040 96%
Cleft palate/uvula 4/43 =0.093 41%
Umbilical hernia 10/100= 0.100 96%
GI reflux 11/100= 0.110 96%
Constipation 12/100= 0.120 96%
Hypothyroidism 10/80= 0.125 77%
Obesity 14/91= 0.154 88%
Hearing loss 17/89= 0.191 86%
Nystagmus 6/23 =0.261 22%
ADHD 14/44= 0.318 42%
Atlanto-axial instability 14/42= 0.333 40%
Acyanotic CHDb 43/103= 0. 417 99%
Presence of any CHDb 44/103= 0.427 99%
Obstructed lacrimal ducts 12/28= 0.429 27%
Dry skin 39/91= 0.429 88%
Malformed teeth 20/46= 0.435 44%
Narrow ear canals 14/31= 0.452 30%
High arched palate 21/45= 0.467 43%
Strabismus 27/58= 0.466 56%
Single transverse palmar crease 44/90= 0.489 87%
Protruding tongue 51/101= 0.505 97%
PE tube placement(s) 40/78= 0.513 75%
Frequent ear infections 45/97= 0.464 93%
Myopia/hyperopia 47/90= 0.522 87%
Brushfield spots 28/48= 0.583 46%
Webbing, short, and/or broad neck 56/96= 0.583 92%
Incurved 5th finger 30/50= 0.600 48%
Stubborn behavior 29/48= 0.604 46%
Epicanthal folds 61/98= 0.622 94%
Small ears 46/74= 0.622 71%
Short hands and fingers 29/45= 0.644 43%
Low set ears 48/74= 0.649 71%
Hyper-extensibility of joints 61/93= 0.656 89%
Hypotonia 65/98= 0.663 94%
Thin, and/or sparse hair 66/98= 0.673 94%
Up-slanted eyes 76/100= 0.760 96%
Brachycephaly 54/71= 0.761 68%
Flat face 78/100= 0.780 96%
Flat nasal bridge 68/80= 0.850 77%
Increased gap between 1st and 2nd toes 44/51= 0.863 49%
a

Number of findings present/total number reported (present or absent).

b

Specific CHD findings are noted in Table IV.

TABLE III.

Summary of Physical Stigmata Reported in 54 Individuals With Non-Mosaic Down Syndrome (Positive Controls)

Clinical finding Proportion
having traita
% reporting
data
(response
rate)
Celiac disease 0/54 = 0 100%
Esophageal stricture 0/54 = 0 100%
Umbilical hernia 0/54 = 0 100%
Cyanotic CHDb 1/54 = 0.019 100%
Hirschsprung’s disease 1/54 = 0.019 100%
Imperforate anus 1/53 = 0.019 98%
Leukemia 1/53 = 0.019 98%
Duodenal stenosis/atresia 3/54 = 0.056 100%
GI reflux 3/54 = 0.056 100%
Congenital/acquired cataracts 4/52 = 0.077 96%
Hearing loss 4/49 = 0.082 91%
Atlanto-axial instability 3/20 = 0.150 37%
Constipation 10/54 = 0.185 100%
ADHD 4/16 = 0.250 30%
Hypothyroidism 13/43 = 0.302 80%
Nystagmus 5/16 = 0.313 30%
Obesity 19/53 = 0.358 98%
Obstructed lacrimal ducts 9/25 = 0.360 46%
Strabismus 9/23 = 0.391 43%
Frequent ear infections 22/53 = 0.415 98%
Brushfield spots 8/19 = 0.421 35%
PE tube placement(s) 24/51 = 0.47 1 94%
Protruding tongue 25/53 = 0.472 98%
Acyanotic CHDb 27/54 = 0.500 100%
Presence of any CHDb 28/54 = 0.519 100%
Flat face 27/53 = 0.509 98%
Webbing, short, and/or broad neck 27/52 = 0.519 96%
Myopia/hyperopia 26/50 = 0.520 93%
Incurved 5th finger 13/23 = 0.565 43%
Thin, and/or sparse hair 31/52 = 0.596 96%
Dry skin 36/54 = 0.667 10%
Single transverse palmar crease 36/52 = 0.692 96%
Low set ears 15/21 = 0714 39%
Flat nasal bridge 19/26 = 0731 48%
Stubborn behavior 19/26 = 0731 48%
Small ears 18/24 = 0750 44%
Increased gap between 1st and 2nd toes 15/20= 0750 37%
Short hands and fingers 19/25 = 0760 46%
Malformed teeth 18/23 = 0783 43%
Epicanthal folds 43/51 = 0.843 44%
Up-slanted eyes 45/53 = 0.849 48%
Hypotonia 46/54 = 0.852 100%
Hyper-extensibility of joints 46/53 = 0.868 98%
Narrow ear canals 1/1 = 1 2%
Cleft uvula and palate 1/1 = 1 2%
High arched palate 3/3 = 1 6%
Brachycephaly 4/4=1 7%
a

Number of findings present/total number reported (present or absent).

b

Specific CHD findings are noted in Table IV.

RESULTS

To date, a total of 107 individuals having mosaicism for trisomy 21 and Down syndrome have been ascertained from families living in the USA, Australia, Canada, Denmark, England, Ireland, Israel, and Portugal. The samples/data materials provided by these propositi are summarized in Table I. Medical records and completed questionnaires were provided for nearly all (97% and 84%, respectively) individuals having mosaicism. The majority of propositi also elected to provide blood specimens (65%) and/or buccal mucosa specimens (55%). Direct physical examinations were completed for 23 of the individuals having mosaicism (the exams were completed in conjunction with the first and third International Mosaic Down Syndrome Association Conventions). Informative photographs (Fig. 1) were provided for 56% of the propositi, with developmental information being provided for 76% of the study subjects having mosaicism.

TABLE I.

Summary of Data Collected and Mean Trisomic Levels for Study Subjects

Lymphocytes
Cultured Research Study
Sample/information collected Number of
samples
Diagnostic
metaphases
Nuclei Metaphases Uncultured
nuclei
Buccal
nuclei
Blooda
  Diagnostic reports 95 51.53 ±2.92
(4.0–95.0)
  Cultured lymphocytes 70 35.12 ±3.52
(3.3–97.0)
  Uncultured lymphocytes 44 30.37 ±3.80
(5.0–91.0)
Buccal smearsb 59 48.89 ±3.02
(4.0–89.4)
Paired specimensc
  Diagnostic cultured blood/research cultured blood 58 46.31 ±376
(4.0–94.0)
33.63 ±3.57
(3.3–91.6)
Research
  Cultured blood/uncultured blood 44 33.15±4.72
(3.3–93.3)
30.37 ±3.80
(5.0–91.0)
  Cultured blood/buccal 49 30.13 ±3.99
(3.6–93.3)
48.06 ±3.44
(4.0–89.4)
  Cultured blood interphase/cultured blood metaphase 57 34.06 ±4.02
(4.8–94.4)
34.15±4.12
(3.3–93.3)
Phenotypic information
  Questionnaire 90
  Pictures 60
  Medical records 104
  Direct physical exam 23
  IQ reports 55
  Developmental information 81
a

The mean ± standard error (range) is shown for all subjects for whom this lymphocyte data was available.

b

The mean ± standard error (range) is shown for all subjects for whom this buccal mucosa cell data was available.

c

The mean ± standard error (range) is shown for all subjects for whom paired comparisons were available (e.g., not all study subjects providing buccal samples also provided blood samples (and vice versa), so the number of paired specimens is less than the total for each specimen type).

FIG. 1.

FIG. 1

Evaluation of propositi with mosaicism for trisomy 21/Down syndrome using photographs. This figure shows photographs of an 11-year-old male who had trisomy for chromosome 21 noted in 20% of his lymphocytes in his diagnostic chromosomal report. The trisomy 21 levels observed at the time of his participation in this research study (at age 11) were 50% for his buccal mucosa cells and 7% for his lymphocytes. The photographs shown here are representative of those used to confirm phenotypic findings reported in medical records and by parents. The types of images requested from the families included (but were not limited to) those showing a full facial view (a); a side profile (b); a close-up view of the mid-face (c); and (d) a view of the mouth. This individual’s ears are slightly small, but normal in shape and position. He also has a mildly broad, but not flat nasal bridge; subtle epicanthal folds; and a high arched palate. [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Tissue-Specific Assessments of the Percentage of Trisomic Cells

The percentages of trisomic cells in the specimens evaluated for the propositi having mosaicism are summarized in Table I and Figure 2. The range was not significantly different in the cultured lymphocytes (3.3–97%) compared to buccal mucosa cells (4.0–89.4%). However, the mean percentage of trisomic cells noted in the buccal mucosa specimens (48.06% ± 3.44%; mean ± SE) was significantly different from that detected in the cultured lymphocytes (30.13 ± 3.99; P< 0.0001), with higher values being seen in 35 of the 49 (71.4%) cases providing both specimens (P< 0.0001). Interestingly, the distribution of trisomic cells observed in the cultured lymphocyte specimens showed a non-random pattern (more cases having lower trisomic values). In contrast, the buccal specimen showed a random pattern (P> 0.05; Fig. 2).

FIG. 2.

FIG. 2

Distribution of the percentage of the cells of the proposita having trisomy for chromosome 21 in cultured lymphocytes and buccal mucosa cells. For the buccal mucosa specimens, the percentage values observed were not significantly different from random expectations. However, for the cultured lymphocytes, a significantly increased number of cases having trisomy 21 in 30% or fewer cells was observed.

To determine the effect, if any, of in vitro culturing on lymphocytes, the proportion of trisomic cells present in cultured lymphocytes (33.15 ±4.72%.) was compared to that observed in the uncultured blood smears (30.37 ± 3.80%). These values were not significantly different (P> 0.05; paired t-test) and were positively correlated (r = 0.97, P< 0.0001).

Assessment of Percentage of Trisomic Cells in Diagnostic Compared to Research Samples

The average age of the propositi at the time of diagnosis was 1.8 years and ranged from the prenatal period to 4 years after birth. The average age at the time of our research study was 6.6 years, with participation ages ranging from 1 month after birth to 43 years of age. In the subset of 58 cases providing both diagnostic reports and research blood specimens, the values reported for the diagnostic samples (46.31 ±3.76%) were significantly different from those noted in the cultured lymphocytes at the time of this research study (33.63 ± 3.57%) [paired t-test (P< 0.0001)]. To determine if the observed difference might be attributable to methodology used for these evaluations (metaphase chromosomes were assessed with GTG-banding in the diagnostic report compared to interphase nuclei using FISH in the research studies), the percentage of trisomic cells observed in both metaphase spreads and interphase nuclei from the same research sample was quantified (Table I). No significant differences were observed between these measurements, the latter of which were significantly correlated (r = 0.99, P< 0.0001).

Evaluations of Phenotypic Findings

Phenotypic information was obtained from medical records, on-site physical examinations, and/or photographs for 104 propositi. The number of clinical traits observed/reported for the propositi with trisomy 21 mosaicism (13.26 ±0.54) was not significantly different from that reported for the non-mosaic positive control group (13.00 ± 0.80)(Fig. 3). The specific physical stigmata evaluated (38 traits) in the individuals with mosaicism and complete trisomy 21/Down syndrome (non-mosaic) are summarized (in increasing frequencies) in Tables II and III, respectively.

FIG. 3.

FIG. 3

Distribution of clinical findings in study subjects having mosaicism compared to non-mosaic (complete) trisomy 21. Individuals with mosaic Down syndrome (n =104) presented with a range of 1–25 findings, compared to cases having complete trisomy 21 (n =54) in whom a range of 3–28 findings was noted.

The overall frequency of congenital heart defects (CHD) was not significantly different between the propositi having mosaicism (41.7%) compared to the non-mosaic positive control group (50%) (Table IV). In particular, the most commonly seen finding in the individuals having mosaicism was an atrial septal defect, which was noted in 29.2% of cases. An atrioventricular canal defect was reported in only 11.1% of the mosaic cases (compared to 22.6% in the positive control group).

TABLE IV.

Congenital Heart Defects (CHD) and IQ Values Reported in Individuals With Mosaicism for Trisomy 21 and Non-Mosaic Trisomy 21

Trait Mosaic trisomy21(n =103) Complete trisomy21(n =54)
(1) Cases having congential heart defect(s) 43 27
  Types of congenital heart defects
    Atrial septal defects 21 (2)a 6 (5)
    Patent ductus arteriosus 17 (2) 9 (4)
    Ventricular septal defect 12 (4) 7 (3)
    Atrioventricular canal defect 8 (8) 7 (7)
    Pulmonic stenosis 6 (0) 0 (0)
    Bicuspid aortic valve 2 (0) 0 (0)
    Mitral valve prolapse 2 (0) 2 (0)
    Congenital missing mitral valve 1 (0) 0 (0)
    Hypoplastic left ventricle 1 (1) 0 (0)
    Pre-excitation syndrome 1 (0) 0 (0)
    Tetralogy of fallot 1 (1) 0 (0)
Total 72 (18)b 31 (19)b
(2) IQ values
  Reported ranges
    30–40 0 1
    41–50 7 7
    51–60 12 1
    61–70 18 6
    71–80 8 3
    81–90 3 0
    91–100 3 0
    > 100 4 0
a

Number of propositi having heart defect (number surgically corrected).

b

Several subjects had more than one heart defect. Thus, the total number of specific defects is greater than the total number of individuals having a congenital heart defect.

In addition to physical traits, IQ testing results were obtained for individuals with mosaicism for trisomy 21 and with complete trisomy 21/Down syndrome (Table IV). The average IQ in individuals with mosaicism for trisomy 21 was significantly higher (mean of 67.35 ±2.31 with a range of 41 to 117) than that of individuals with complete trisomy 21/Down syndrome (mean of 57.67 ± 3.17 and range of 36–75; P =0.03).

The ages at which developmental milestones where achieved in individuals with mosaicism (n = 81), their siblings (n = 106), and individuals with complete trisomy 21/Down syndrome (n = 50) were also compared (Fig. 4). Individuals with mosaic trisomy 21/Down syndrome attained all milestones at a significantly later age than their chromosomally normal siblings (P<0.05), but tended to attain milestones earlier than the age-matched, non-mosaic individuals. Significant decreases were observed for the age that the mosaic propositi first crawled (P = 0.004), walked (P = 0.013), and independently dressed themselves (P = 0.030) when compared to the individuals having complete trisomy 21.

FIG. 4.

FIG. 4

Comparison of the average ages of developmental milestone attainment. Individuals with mosaic Down syndrome (gray histograms) attained all milestones at a significantly later age than their chromosomally normal siblings (white histograms). However, with the exception of rolling over, speaking and drinking from a cup, there was a general trend for individuals with mosaic trisomy 21/Down syndrome to achieve milestones at an earlier age than individuals with full (complete) trisomy 21 Down syndrome (black histogram). (Bars denote standard error)

Latent Class Analysis (LCA) of Phenotype

To determine if the subjects with mosaic trisomy 21 had sufficient differences in their phenotype (presence or absence of traits) to allow them to be partitioned into distinct groups, 104 subjects were evaluated using a LCA. The best fit for the data was obtained for a model that partitioned the propositi into two groups having fewer (class 1) or more (class 2) phenotypic traits (1 vs. 2 class model P = 0.0022; 2 vs. 3 class model P = 0.1203). The proportion of trisomic cells (from diagnostic reports) of the 60 individuals assigned to class 1 (43.84 ±%) was significantly lower than that of the 44 individuals assigned to class 2 (59.76 ± %; P = 0.0072). In addition, the mean percentage of trisomic cells in the buccal samples from individuals in class 1 (42.09%) was significantly lower than the values from the propositi in class 2 (57.11%) (P = 0.0156). The greatest discrepancies in phenotype that allowed for the distinction between the members of class 1 and class 2 were seen for the presence/absence of: (1) acyanotic congenital heart defects (CHD); (2) total (acyanotic and cyanotic) CHD; and (3) umbilical hernias (Fig. 5a).

FIG. 5.

FIG. 5

Latent class analysis of individuals with mosaicism for trisomy 21 (a) without training variables (model 1) and (b) with training variables (individuals with full trisomy 21) [model 2]. a: A graphical representation of the conditional response probabilities for class 1 (squares [solid line]) and class 2 (circles [hatched line]) are shown. The traits that most clearly distinguished the two classes included hearing loss; small ears; low-set ears;cardiac anomalies; brachycephaly; and hernias.b: A graphical representation of the conditional response probabilities for both class1(squares [solid line]) and class 2 (circles [hatched line]) are shown. Under this model (which incorporated training variables) the data point curves are separated for the majority (76%) of traits studied. X-axis abbreviations: * Flat Face (flatface); Flat Nasal Bridge (flatnasal); Upslanted Eyes (upslanteye); Epicanthal Folds (epifolds); Myopia (myopia); Hearing Loss (hearing); PE Tubes (petubes); Small Ears (smallears); Low-set Ears (lowears); Frequent Ear Infections (earinfect); Protruding Tongue (ptongue); Dry Skin (dryskin); Single Transverse Palmar Crease (Palmar); Thin, or Sparse Hair (Thinhair); Hypotonia (hypotonia); Acyanotic Congenital Heart Defects (acyanotic); Presence of Cyanotic and Acyanotic Heart Defects (anyheart); Brachycephaly (brachyceph); Hyperextensibility of Joints (hyperjoint); Webbing, Short, or Broad Neck (webneck); Umbilical Hernia (hernia);GI Reflux (gireflux); Constipation (constipation); Hypothyroid (hypothyroid); Obesity (obesity). Y-axis shows the probability of answering “yes” to a query regarding the presence of a particular phenotypic feature.

A second LCA analysis was also done to determine if improvements in phenotypic distinctions for the mosaic propositi (same 104 subjects evaluated above) could be made by comparing their phenotypic data with that of the 54 positive control individuals having complete trisomy 21 (total n = 158; Fig. 5b). In this model, the subjects with complete non-mosaic trisomy 21 were restricted to a single class, but the individuals with mosaicism for trisomy 21 could be partitioned into any class, based on their phenotype. Using this approach, a two-class model still provided the best fit to the data. The 20 individuals categorized into class 1 presented with fewer phenotypic findings and had a significantly lower proportion of trisomic cells (mean of 37.34%) than the 84 mosaic propositi categorized as belonging to class 2 (phenotype similar to complete trisomy 21/Down syndrome; mean of 53.97%; P = 0.0189). This second LCA model, using data from positive control subjects as “training variables,” resulted in non-overlapping distributions for 19 of the 25 traits observed in the propositi with mosaicism (Fig. 5b) and allowed for improvements (visualized as higher values for the differences between class probabilities) in the distinction of classes (compared to model 1) for all traits but hearing loss, acyanotic CHD, total CHD, hernias, and constipation. Under model 2, the greatest distinctions between the 2 classes were observed for the presence/absence of the following phenotypic traits: (1) epicanthal folds; (2) brachycephaly; (3) hyperextensibility of joints; and (4) webbing, short, or broad neck.

Correlations Between Percentage of Cells With Trisomy 21 and Tissue-Specific Findings

Interestingly, a significant inverse correlation (r=−0.53; P = 0.0094) was observed between the percentage of trisomic cells present in the buccal samples and the IQ scores of the mosaic propositi. Although a similar trend was observed between the IQ values and percentage of trisomic cells in the blood samples, this correlation was not significant (P = 0.1998). In addition, a contingency chi-square test was used to determine if there was any relationship between the proportion of trisomic cells in the study subjects and the presence of congenital heart defects. Intriguingly, there was a significant relationship between the presence of CHD and the proportion of trisomic cells in blood specimens (P = 0.0286), with higher blood trisomy levels (59.26 ±4.38%) being associated with CHD, while lower trisomic percentages (43.84 ± 3.81%) were associated with fewer cases of CHD. Although a similar trend was seen between buccal mucosa trisomy levels and CHD, this relationship was not significant.

DISCUSSION

The differing percentages of trisomic and euploid cells in individuals with mosaicism for trisomy 21 provide an opportunity to assess the extent to which phenotypic variability is related to the varying proportion and/or tissue distribution of the trisomic cells. In this study, buccal cells showed a significantly higher level of trisomy than lymphocytes. This difference could not be attributed solely to in vitro culturing since the percentage of trisomic cells in cultured and uncultured lymphocytes was not significantly different.

One possible factor contributing to the observed difference in trisomy levels between specimens is that these tissues have varying in vivo selection rates due to inherently different cell turnover and/ or growth rates of blood and buccal samples. In one of the few reports detailing the kinetics of normal lymphocytes and buccal epithelia, Hellerstein et al. [1999] noted that, in healthy individuals, CD4 and CD8 T cells have a half-life of approximately 87 and 77 days, respectively. In contrast, the turnover times seen in buccal epithelial cells have been reported to vary from 5 to 25 days [Gillespie, 1969; Alvares et al., 1972]. Collectively, the findings of these two studies suggest that lymphocytes have a lower turnover rate than buccal cells. Therefore, if in vivo selection (acting against replicating trisomic cells) is largely responsible for the difference in trisomy levels observed between the tissues of the subjects in this study, one might expect to detect an overall higher trisomic percentage for the lymphocytes compared to buccal cells since they have a lower cell turnover rate. However, the opposite trend was observed. Thus, the observed variation in trisomy level between tissues may, instead, be a manifestation of differences in the distribution of mosaic cells during development or possibly be attributable to selection differences that are not simply a reflection of the number of cell cycles completed after birth.

In addition to differences in the level of trisomy between tissues, investigators have also reported changes in the percentage of cells having trisomy 21 over time in individuals with both mosaicism for trisomy 21 and non-mosaic (complete) trisomy 21 [Taylor, 1968, 1970; Taysi et al., 1970; Wilson et al., 1980; Jenkins et al., 1997]. In this current study, diagnostic analyses (which tended to be completed in the first 2 years of life) showed significantly higher levels of trisomy than assessments at later ages (as part of this research protocol). Possible explanations for the observed differences include (but are not limited to): (1) in vivo selection against trisomic lymphocytes that may occur over time; (2) a bias in the initial diagnostic study to identify metaphases having a trisomic compared to euploid complement; or (3) a difference in the proportion of trisomic cells present in interphase nuclei compared to metaphase spreads. However, this latter hypothesis was not supported by our data, which showed no significant difference in the proportion of trisomic cells noted in the metaphase compared to interphase cells evaluated from 57 individuals. Thus, the causes for the observed changes in the frequency of trisomic cells over time, if present, remain unclear (requiring additional assessment in a long-term, longitudinal study design [ideally assessing buccal cells as well as lymphocytes] to better characterize).

When evaluating phenotype, the mean IQ level of the mosaic propositi in this study was significantly higher than the mean IQ reported for individuals with complete trisomy 21 (10 points higher). This result is in agreement with the findings of previous investigations, where IQ values were noted to be 10–30 points higher for cases with mosaicism [Wunsch, 1957; Fishler et al., 1976]. This result, coupled with the observation that the average age at which mosaic propsoti attained developmental milestones was between the average ages reported for their siblings and for individuals with complete trisomy 21/Down syndrome, suggests that as a group, individuals with mosaicism for trisomy 21 tend to have less intellectual and developmental impairments than individuals with complete trisomy 21. Nevertheless, it is important to point out that, just as in the case of chromosomally normal individuals, one cannot accurately predict the specific intellectual capacity of individuals with trisomy 21 mosaicsim or complete trisomy 21 since this trait is determined by many factors.

In order to better characterize the phenotype among individuals with mosaicism for trisomy 21 in Down syndrome, a latent class analysis was performed. Models run with and without training variables resulted in the distinction of two phenotypic subtypes. The mosaic propositi in the class having more clinical traits had higher frequencies of trisomic cells. This finding suggests that the level of trisomy is positively correlated to the severity of the phenotype.

As a final assessment, correlations between the phenotypic findings and the tissue specific level of trisomic cells were examined. A significant inverse correlation was observed between the percentage of trisomic cells present in the propositi’s buccal samples and their IQ scores (but not lymphocytes). Thus, the level of trisomy 21 in buccal samples may be a better predictor of developmental progress than lymphocytes. One can speculate that this correlation results from the fact that brain cells, like buccal cells, are ectodermally derived [Larsen, 2001]. Interestingly, the presence or absence of CHD was more closely associated with trisomy 21 levels in lymphocytes than buccal cells. This may reflect the fact that both blood and heart tissues are derived from the mesoderm layer [Larsen, 2001]. An unexpected finding of this study was the observation that the individuals with mosaicism for trisomy 21 presented with more types of CHD than the positive control group having complete trisomy 21/Down syndrome. Interestingly, they also had a significantly lower number of defects that required surgery. Given that atrioventricular canal defects are treated surgically, the reduced frequency of this type of CHD in the mosaic population was of clinical relevance since it lessened their risk for cardiac morbidity.

In conclusion, the data derived from our studies suggest that the proportion of trisomic cells present in tissues of different embryologic origin (e.g., blood and buccal mucosa) influences the phenotypic outcome associated with mosaicism for trisomy 21 in Down syndrome. Thus, an analysis of different tissue samples should be considered when evaluating individuals with trisomy 21 mosaicism and Down syndrome. Collectively, the findings of our studies have helped to further clarify our understanding of the phenotypic variation seen in persons with mosaicism for trisomy 21.

ACKNOWLEDGMENTS

This study was done through the cooperation of many generous individuals, many of whom are members of the International Mosaic Down Syndrome Association. This study was also funded, in part, by a grant (CJC) from the National Institute of Environmental Health (R01 ES12074). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NIH.

REFERENCES

  1. Alvares O, Skougaard MR, Pindborg JJ, Roed-Petersen B. In vitro incorporation of tritiated thymidine in oral homogeneous leukoplakias. Scand J Dent Res. 1972;80:510–514. doi: 10.1111/j.1600-0722.1972.tb00321.x. [DOI] [PubMed] [Google Scholar]
  2. Bhatt S, Schreck R, Graham JM, Korenberg JR, Hurvitz CG, Fischel-Ghodsian N. Transient leukemia with trisomy 21: Description of a case and review of the literature. Am J Med Genet. 1995;58:310–314. doi: 10.1002/ajmg.1320580404. [DOI] [PubMed] [Google Scholar]
  3. Dewald G, Stallard R, Al Saadi A, Arnold S, Bader PI, Blough R, Chen K, Elejalde BR, Harris CJ, Higgins RR, Hoeltge GA, Hsu W-T, Kubic V, McCorquodale DJ, Micale MA, Moore JW, Phillips RM, Scheib-Wixted S, Schwartz S, Siembieda S, Strole K, VanTuinen P, Vance GH, Wiktor A, Wise L, Yung J-F, Zenger-Hain J, Zinsmeister A. A multi-center investigation with interphase in situ hybridization using X- and Y-chromosome probes. Am J Med Genet. 1998;76:318–326. [PubMed] [Google Scholar]
  4. Epstein CJ, Korenberg JR, Anneren G, Antonarakis SE, Ayme S, Courchesne E, Epstein LB, Fowler A, Groner Y, Huret JL, Kempler TL, Lott IT, Lubin BH, Magenis E, Opitz J, Patterson D, Priets JH, Pueschel SM, Rapoport SI, Sinet PM, Tanzi RE, de la Cruz F. Protocols to establish genotype-phenotype correlations in Down syndrome. Am J Med Genet. 1991;49:207–235. [PMC free article] [PubMed] [Google Scholar]
  5. Finley WH, Finley SC, Rosecrans CJ, Tucker CC. Normal/trisomy 21 mosaicism. Report of four cases and review of the subject. Am J Dis Child. 1966;112:444–447. doi: 10.1001/archpedi.1966.02090140116010. [DOI] [PubMed] [Google Scholar]
  6. Fishler K, Koch R. Mental development in Down syndrome mosaicism. Am J Ment Retard. 1991;96:345–351. [PubMed] [Google Scholar]
  7. Fishler K, Koch R, Donnell GN. Comparison of mental development in individuals with mosaic and trisomy 21 Down’s syndrome. Pediatrics. 1976;58:744–748. [PubMed] [Google Scholar]
  8. Gillespie GM. Renewal of buccal epithelium. OralSurg Oral Med Oral Pathol. 1969;27:83–89. doi: 10.1016/0030-4220(69)90033-4. [DOI] [PubMed] [Google Scholar]
  9. Hamerton JL, Giannelli F, Polani PE. Cytogenetics of Down’s syndrome (Mongolism) I. Data on a consecutive series of patients referred for genetic counseling and diagnosis. Cytogenetics. 1965;104:171–185. doi: 10.1159/000129853. [DOI] [PubMed] [Google Scholar]
  10. Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R, Neese R, Macallan D, Deeks S, McCune JM. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999;5:83–89. doi: 10.1038/4772. [DOI] [PubMed] [Google Scholar]
  11. Hook EB. Down syndrome: Frequency in human populations and factors pertinent to variation in rates. In: de la Cruz FF, Gerald PS, editors. Trisomy 21 (Down syndrome): Research perspectives. Baltimore: University Park Press; 1981. pp. 3–67. [Google Scholar]
  12. Jenkins EC, Schupf N, Genovese M, Ye LL, Kapell D, Canto B, Harris M, Devenny D, Lee JH, Brown WT. Increased low-level chromosome 21 mosaicism in older individuals with Down syndrome. Am J Med Genet. 1997;68:147–151. doi: 10.1002/(sici)1096-8628(19970120)68:2<147::aid-ajmg5>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  13. Johnson RC, Abelson RB. Intellectual, behavioral, and physical characteristics associated with trisomy, translocation, and mosaic types of Down’s syndrome. Am J Ment Defic. 1969;73:852–855. [PubMed] [Google Scholar]
  14. Larsen WJ. Development of the limbs. In: Sherman LS, Potter SS, Scott WJ, editors. Human embryology. New York: Churchill Livingstone; 2001. p. 327. [Google Scholar]
  15. Leach NT, Rehder C, Jensen K, Holt S, Jackson-Cook C. Human chromosomes with shorter telomeres and large heterochromatin regions have a higher frequency of acquired somatic cell aneuploidy. Mech Ageing Dev. 2004;125:563–573. doi: 10.1016/j.mad.2004.06.006. [DOI] [PubMed] [Google Scholar]
  16. Mikkelsen M. Down syndrome: Cytogenetical epidemiology. He-reditas. 1977;86:45–50. doi: 10.1111/j.1601-5223.1977.tb01211.x. [DOI] [PubMed] [Google Scholar]
  17. Moorhead PS, Nowell PC, Mellman WJ, Battips DM, Hungerford DA. Chromosome preparations of leukocytes cultured from human peripheral blood. Exp Cell Res. 1960;20:613–616. doi: 10.1016/0014-4827(60)90138-5. [DOI] [PubMed] [Google Scholar]
  18. Muthén LK, Muthén BO. Mplus: User’s Guide. Los Angeles, CA: Muthén and Muthén; 1998. [Google Scholar]
  19. Nussbam RL, McInnes RR, Willard HF. Thompson & Thompson: Genetics in Medicine. 6th edition. Philadelphia: W.B: Saunders Company; 2001. pp. 157–162. [Google Scholar]
  20. Pangalos C, Avramopoulos D, Blouin JL, Raoul O, deBlois MC, Prieur M, Schinzel AA, Gika M, Abazis D, Antonarakis SE. Understanding the mechanism(s) of mosaic trisomy 21 by using DNA polymorphism analysis. Am J Hum Genet. 1994;54:473–481. [PMC free article] [PubMed] [Google Scholar]
  21. Papavassiliou P. Diss. Virginia Commonwealth University, 2007. Ann Arbor: ProQuest UMI Dissertations Publishing; 2007. Karyotype-phenotype correlations for mosaic Down syndrome. 2008.AAT 3283127. [Google Scholar]
  22. Patterson D, Costa ACS. Down syndrome and genetics—A case of linked histories. Nat Rev Genet. 2005;6:137–147. doi: 10.1038/nrg1525. [DOI] [PubMed] [Google Scholar]
  23. Richards BW. Mosaic mongolism. J Ment Defic Res. 1969;13:66–83. doi: 10.1111/j.1365-2788.1969.tb01067.x. [DOI] [PubMed] [Google Scholar]
  24. Shipe D, Reisman LE, Chung CY, Darnell A, Kelly S. The relationship between cytogenetic constitution, physical stigmata, and intelligence in Down’s syndrome. Am J Ment Defic. 1968;72:789–797. [PubMed] [Google Scholar]
  25. Taylor AI. Cell selection in vivo in normal/G trisomic mosaics. Nature. 1968;219:1028–1030. doi: 10.1038/2191028a0. [DOI] [PubMed] [Google Scholar]
  26. Taylor AI. Further observation of cells election in vivo in normal/G trisomic mosaics. Nature. 1970;227:163–164. doi: 10.1038/227163a0. [DOI] [PubMed] [Google Scholar]
  27. Taysi K, Kohn G, Mellman WJ. Mosaic mongolism II. Cytogenetic studies. J Pediatr. 1970;76:880–885. doi: 10.1016/s0022-3476(70)80369-9. [DOI] [PubMed] [Google Scholar]
  28. Wilson MG, Towner JW, Forsman I. Decreasing mosaicism in Down’s syndrome. Clin Genet. 1980;17:335–340. doi: 10.1111/j.1399-0004.1980.tb00159.x. [DOI] [PubMed] [Google Scholar]
  29. Wunsch WL. Some characteristics of Mongoloids evaluated in a clinic for children with retarded mental development. Am J Ment Defic. 1957;62:122–130. [PubMed] [Google Scholar]

RESOURCES